<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648891</url>
  </required_header>
  <id_info>
    <org_study_id>20-006889</org_study_id>
    <nct_id>NCT04648891</nct_id>
  </id_info>
  <brief_title>Spasmodic Dysphonia Pain</brief_title>
  <official_title>Spasmodic Dysphonia Pain Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to identify adjuvant methods to improve patient comfort during in-office&#xD;
      laryngology procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      The use of local anesthetic or vibrating instrument will decrease overall pain experienced by&#xD;
      a patient with spasmodic dysphonia undergoing Botox injections.&#xD;
&#xD;
      Aims, purpose, or objectives:&#xD;
&#xD;
      To identify adjuvant methods to improve patient comfort during in-office laryngology&#xD;
      procedures. Results demonstrated here should be transferrable to other transcutaneous&#xD;
      in-office procedures in laryngology.&#xD;
&#xD;
      Background:&#xD;
&#xD;
      Spasmodic dysphonia is a vocal disorder characterized by uncontrollable voice breaks.&#xD;
      Injection of botulinum neurotoxin into the laryngeal muscles is the mainstay of treatment.&#xD;
      Patients require repeated treatments due to the temporary effect of botulinum neurotoxin.&#xD;
      Laryngeal injections are commonly performed through the skin of the neck and can be&#xD;
      associated with pain and discomfort. Local anesthetic administration prior to laryngeal&#xD;
      injection is commonly performed in clinical practice, however its efficacy hasn't been&#xD;
      evaluated and a third of surveyed otolaryngologists do not administer local anesthesia prior&#xD;
      to the laryngeal injection of botulinum neurotoxin. Vibratory anesthesia involves the&#xD;
      application of a local vibratory stimulus and has been found to reduce pain during various&#xD;
      needle-related procedures. Vibratory anesthesia has not previous been evaluated for laryngeal&#xD;
      injections.&#xD;
&#xD;
      This study will utilize the need for spasmodic dysphonia patients to receive repeated&#xD;
      injections to incorporate a crossover design where patients receive three consecutive&#xD;
      laryngeal injections of botulinum toxin experiencing injection without additional anesthesia,&#xD;
      with local anesthesia, and with vibration anesthesia in a randomized order.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain experienced</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Measured on a Visual Analogue Scale where 0 = no pain and 10 = worst pain</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Spasmodic Dysphonia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive laryngeal injection of Botox via a transcricothyroid approach without additional anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive laryngeal injection of Botox via a transcricothyroid approach following subcutaneous injection of 0.5cc 2% lidocaine in 1:100,000 epinephrine (done approximately 2 minutes before Botox injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vibrating Wand</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive laryngeal injection of Botox via a transcricothyroid approach while a vibrating instrument is held adjacent to cricothyroid space</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Subcutaneous lidocaine injection prior to laryngeal injection</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vibrating wand</intervention_name>
    <description>Concomitant use of vibrating wand during laryngeal injection</description>
    <arm_group_label>Vibrating Wand</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Laryngeal injection without additional anesthesia</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Spasmodic dysphonia with or without tremor&#xD;
&#xD;
          -  Receiving botox as treatment via a transcricothyroid approach&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Allergy to lidocaine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Karle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Heyes, MBChB</last_name>
    <phone>480-342-2983</phone>
    <email>Heyes.Richard@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>William (Will) E. Karle, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysphonia</mesh_term>
    <mesh_term>Hoarseness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

